Aprotinin in Primary Cardiac Surgery: Operative Outcome of Propensity Score-Matched Study

Annals of Thoracic Surgery

Volumn 86, Issue 4, 2008, Pages 1195-1202

  Ngaage, Dumbor L ^a   Cale, Alexander R ^a   Cowen, Michael E ^a   Griffin, Steven ^a   Guvendik, Levant ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; HEPARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CLOTTING; BLOOD TRANSFUSION; CONTROLLED STUDY; CONVALESCENCE; DRUG DOSE REGIMEN; DRUG INDICATION; EMERGENCY SURGERY; FEMALE; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART SURGERY; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SURGICAL MORTALITY; SYMPTOMATOLOGY; THROMBOSIS; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; APROTININ; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CASE-CONTROL STUDIES; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS IMPLANTATION; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS; PROBABILITY; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 52049123335     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2008.06.048     Document Type: Article

References (40)

1. Tice D.A., Worth Jr. M.H., Clauss R.H., and Reed G.H. The inhibition of Trasylol of fibrinolytic activity associated with cardiovascular operations. Surg Gynecol Obstet 119 (1964) 71-74
2. Bailey C.R., Kelleher A.A., and Wielogorski A.K. Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery. Br J Surg 81 (1994) 969-973
3. Fergusson D., Glass K.C., Hutton B., and Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding?. Clin Trials 2 (2005) 218-229 discussion 29-32
4. Laupacis A., and Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 85 (1997) 1258-1267
5. Beath S.M., Nuttall G.A., Fass D.N., Oliver Jr. W.C., Ereth M.H., and Oyen L.J. Plasma aprotinin concentrations during cardiac surgery: full- versus half-dose regimens. Anesth Analg 91 (2000) 257-264
6. Dietrich W., Busley R., and Kriner M. High-dose aprotinin in cardiac surgery: is high-dose high enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg 103 (2006) 1074-1081
7. Brown J.R., Birkmeyer N.J., and O'Connor G.T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115 (2007) 2801-2813
8. Cosgrove III D.M., Heric B., Lytle B.W., et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 54 (1992) 1031-1036 discussion 6-8
9. Furnary A.P., Wu Y., Hiratzka L.F., Grunkemeier G.L., and Page III U.S. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 116 11 suppl (2007) I127-I133
10. Levi M., Cromheecke M.E., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 354 (1999) 1940-1947
11. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
12. Van der Linden P.J., Hardy J.F., Daper A., Trenchant A., and De Hert S.G. Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome?. Br J Anaesth 99 (2007) 646-652
13. Ferraris V.A., Ferraris S.P., Saha S.P., et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 83 5 suppl (2007) S27-S86
14. Levy J.H., Pifarre R., Schaff H.V., et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 92 (1995) 2236-2244
15. Royston D., Bidstrup B.P., Taylor K.M., and Sapsford R.N. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 2 (1987) 1289-1291
16. McEvoy M.D., Reeves S.T., Reves J.G., and Spinale F.G. Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg 105 (2007) 949-962
17. Shigeta O., Kojima H., Jikuya T., et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation 96 (1997) 569-574
18. Rossi M., Storti S., Martinelli L., et al. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system. J Cardiothorac Vasc Anesth 11 (1997) 835-839
19. Kincaid E.H., Ashburn D.A., Hoyle J.R., Reichert M.G., Hammon J.W., and Kon N.D. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery?. Ann Thorac Surg 80 (2005) 1388-1393 discussion 93
20. Bedirhan M.A., Turna A., Yagan N., and Tasci O. Aprotinin reduces postoperative bleeding and the need for blood products in thoracic surgery: results of a randomized double-blind study. Eur J Cardiothorac Surg 20 (2001) 1122-1127
21. Schneeweiss S., Seeger J.D., Landon J., and Walker A.M. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 358 (2008) 771-783
22. Shaw A.D., Stafford-Smith M., White W.D., et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 358 (2008) 784-793
23. D'Ambra M.N., Akins C.W., Blackstone E.H., et al. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 112 (1996) 1081-1089
24. Sedrakyan A., Wu A., Sedrakyan G., Diener-West M., Tranquilli M., and Elefteriades J. Aprotinin use in thoracic aortic surgery: safety and outcomes. J Thorac Cardiovasc Surg 132 (2006) 909-917
25. Matching: Multivariate and propensity score matching with balance optimization. R package version 4.5-3 (2007). http://sekhon.berkeley.edu/matching
26. R: A language and environment for statistical computing. R Foundation for Statistical Computing (2007). http://www.r-project.org
27. Dietrich W., Busley R., and Boulesteix A.L. Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin. Anesthesiology 108 (2008) 189-198
28. Iwata Y., Nicole O., Okamura T., Zurakowski D., and Jonas R.A. Aprotinin confers neuroprotection by reducing excitotoxic cell death. J Thorac Cardiovasc Surg 135 (2008) 573-578 discussion 578
29. Mouton R., Finch D., Davies I., Binks A., and Zacharowski K. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet 371 (2008) 475-482
30. Pagano D., Howell N.J., Freemantle N., et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 135 (2008) 495-502
31. Fergusson D.A., Hebert P.C., Mazer C.D., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 (2008) 2319-2331
32. Taggart D.P., Djapardy V., Naik M., and Davies A. A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting. J Thorac Cardiovasc Surg 126 (2003) 1087-1094
33. Schweizer A., Hohn L., Morel D.R., Kalangos A., and Licker M. Aprotinin does not impair renal haemodynamics and function after cardiac surgery. Br J Anaesth 84 (2000) 16-22
34. Lemmer Jr. J.H., Stanford W., Bonney S.L., et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 107 (1994) 543-551 discussion 51-3
35. Harmon D.C., Ghori K.G., Eustace N.P., O'Callaghan S.J., O'Donnell A.P., and Shorten G.D. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. Can J Anaesth 51 (2004) 1002-1009
36. Eser O., Kalkan E., Cosar M., et al. The effect of aprotinin on brain ischemic-reperfusion injury after hemorrhagic shock in rats: an experimental study. J Trauma 63 (2007) 373-378
37. Lazar H.L., Bao Y., Tanzillo L., et al. Aprotinin decreases ischemic damage during coronary revascularization. J Card Surg 20 (2005) 519-523
38. Cumming A.D., and Nimmo G.R. Hemodynamic, renal, and hormonal actions of aprotinin in an ovine model of septic shock. Crit Care Med 20 (1992) 1134-1139
39. Colwell Jr. C.W., Chelly J.E., Murkin J.M., et al. Randomized study of aprotinin effect on transfusions and blood loss in primary THA. Clin Orthop Relat Res 465 (2007) 189-195
40. Robinson J., Nawaz S., and Beard J.D. Randomized, multicentre, double-blind, placebo-controlled trial of the use of aprotinin in the repair of ruptured abdominal aortic aneurysm. On behalf of the Joint Vascular Research Group. Br J Surg 87 (2000) 754-757